Acadia Pharma GAAP EPS of $0.42 beats by $0.28, revenue of $278.6M beats by $2.06M

At September 30, 2025, Acadia’s cash, cash equivalents and investment securities totaled $847.0 million, compared to $756.0 million at December 31, 2024.

Full Year 2025 Financial Guidance

Acadia is updating its 2025 guidance:

• Total Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance range of $1.045 to $1.095 billion^*.
• NUPLAZID net product sales in the range of $685 to $695 million, compared with the prior guidance range of $665 to $690 million.
• DAYBUE net product sales in the range of $385 to $400 million, compared with the prior guidance range of $380 to $405 million^*.
• R&D expense in the range of $335 to $345 million, compared with the prior guidance range of $330 to $350 million.
• SG&A expense in the range of $540 to $555 million, compared with the prior guidance range of $535 to $565 million.